Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review
- 2 Downloads
Granuloma annulare (GA) is the most common non-infectious disease. Despite the fact that it is a benign disease, it can be associated with a variety of disorders and certain drugs including biological disease-modifying anti-rheumatic drugs (bDMARDs). A 50-year-old man with a history of rheumatoid arthritis refractory to methotrexate, hydroxychloroquine and infliximab was treated with tocilizumab (TCZ), an interleukin-6 receptor antagonist, 162 mg subcutaneously every week. The patient responded very well to TCZ treatment with a decrease of acute phase reactants and reduction of disease activity score for 28-joints count. However, 3 months later he developed erythematous polycyclic eruptions affecting the lower extremities consistent with a diagnosis of GA which was confirmed by a skin biopsy. TCZ has been discontinued and the patient was treated with prednisone presenting complete resolution of skin manifestations after 4 weeks. This is the first case of GA development during TCZ treatment. Thus, we review the literature and discuss the relevant cases of GA development in patients treated with bDMARDs. When dealing with patients treated with these agents, all physicians should be aware of possible adverse events and the potential development of such complications.
KeywordsGranuloma annulare Rheumatoid arthritis Interleukin-6 inhibitors Tocilizumab
EP: acquisition and analysis of the data, and manuscript drafting. AP-B: analysis and interpretation of the histological data. PVV: acquisition, analysis and interpretation of the data. AAD: review of the manuscript and final approval.
Compliance with ethical standards
Conflict of interest
E. Pelechas, Alexandra Papoudou-Bai, Paraskevi V. Voulgari, and Alexandros A. Drosos declare no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from our patient included in the study.
- 1.Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. (2018) Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum. https://doi.org/10.1016/j.semarthrit.2018.06.003 (epub ahead of print) CrossRefGoogle Scholar
- 5.Markatseli TE, Kaltsonoudis ES, Voulgari PV, Zioga A, Drosos AA (2009) Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol 27:996–998Google Scholar
- 6.Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA (2014) Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther 16:R125. https://doi.org/10.1186/ar4582 CrossRefPubMedCentralGoogle Scholar
- 15.Clark ML, Tobin CA, Sutton A, Missall TA. Granuloma annulare in the setting of secukinumab. Case Rep Dermatol Med 2018:5175319. https://doi.org/10.1155/2018/5175319
- 18.Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, Bütikofer L, Seitz M, Reichenbach S (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921–1927. https://doi.org/10.1016/S0140-6736(16)00560-2 CrossRefGoogle Scholar